GlassScriptPhysician profile
Paul C Lee
NPI 1003078981
$7,686.25
in general payments reported to CMS, 2019-2025
19 companies · $587 in 2025
The $587 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $422 · 2021: $532 · 2022: $846 · 2023: $2,633 · 2024: $1,504 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,964 · Travel and Lodging: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,964.43 |
| Travel and Lodging | $759.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,521.07 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Medtronic USA, INC. | $791.96 | 2019-2020 | |
| Boston Scientific Corporation | $717.63 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Infinion 16 |
| Nalu Medical, INC. | $555.78 | 2023-2024 | Nalu Neurostimulation System |
| Abbott Laboratories | $501.87 | 2019-2024 | Proclaim, Cardiomems |
| Merz North America, INC. | $303.64 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $287.41 | 2021-2025 | Xeomin |
| Nevro Corp. | $192.14 | 2020-2023 | Senza |
| Spinesmith Holdings, LLC | $182.07 | 2019 | |
| Mml US, INC. | $155.44 | 2023 | Reactiv8 |
| Avanos Medical | $140.60 | 2023 | Pnb and Accessories |
| Globus Medical, INC. | $134.28 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.30 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $30.08 | 2025 | |
| Spr Therapeutics, INC | $27.30 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.18 | 2019 | |
| Depuy Synthes Sales INC. | $25.06 | 2024 | Monovisc |
| Ermi LLC | $18.10 | 2019 | |
| Metacel Pharmaceuticals LLC | $15.34 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.